Zepbound may not be as widely known as its competitors, but the weight-loss drug may soon be more accessible than the rest.
Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback